Roche and ICN Settle Patent Dispute over Drug
January 9, 2003
The Roche Group has settled a patent dispute with ICN Pharmaceuticals and its Ribapharm unit over the standard hepatitis therapy ribavirin, clearing the way for Roche to sell a hepatitis drug. The companies gave no financial terms, but said all legal action over ribavirin would stop, and Roche will keep marketing its own branded version, Copegus, worldwide. Roche developed Copegus on its own, but it has the same active ingredient as ribavirin. Ribapharm will license ribavirin to Roche. The agreement permits Roche to sell the hepatitis C drug Pegasys in combination with Copegus.Adapted from:
New York Times
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.